Cancer patients could be more susceptible to SARS-CoV-2 infection and development of related complications. The current data about NENs and SARS-CoV-2 are scattered and mainly related to a single country or institution and it is unclear if patients with neuroendocrine neoplasms (NENs) should be considered and managed similarly to cancer patients in general. All of this, combined with the rarity and heterogeneity of NENs will make it quite difficult to have homogeneous information and recommendations about clinical management of NEN patients during the COVID-19 pandemic.

Therefore, a global database has been created for NEN patients who are SARS-CoV-2 positive, named INTENSIVE (InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients). International data collection will be coordinated by the European Institute of Oncology, IEO, in Milan, Italy, with Dr. Nicola Fazio as Principal Investigator. Identifier: NCT04444401

INCA has gladly endorsed this important initiative. The registry will include as many countries and centers dealing with NEN as possible to have the largest view of this topic.

Although cases of SARS-CoV-2 positive NEN patients can be reported to other registries or databases, this does not overlap with the main goal of the INTENSIVE initiative, which is to get the largest and most globally representative collection of data for SARS-CoV-2 positive NEN patients. This will be very useful to draw specific indications for clinical practice, such as which NEN patients are at higher risk of infection by SARS-CoV-2 and developing related clinical complications, and how to manage NEN/COVID-19 patients and their cancer treatments.

Every participant center will be provided with a center ID for which all de-identified patient data can be entered, in addition to a protocol template to obtain local IRB approval. It should be noted that the local IRB approval is required before any data is actually entered in the system. In case of interest in contributing to the international registry, please see below for the contact details of the investigator team:

Dr. Nicola Fazio               Principal Investigator        

Dr. Francesca Spada       Sub Investigator               

Dr. Lorenzo Gervaso       Sub Investigator                

Dr. Darina Tamayo         Trial Coordinator